CN111057736B - 一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 - Google Patents
一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 Download PDFInfo
- Publication number
- CN111057736B CN111057736B CN202010008836.1A CN202010008836A CN111057736B CN 111057736 B CN111057736 B CN 111057736B CN 202010008836 A CN202010008836 A CN 202010008836A CN 111057736 B CN111057736 B CN 111057736B
- Authority
- CN
- China
- Prior art keywords
- boc
- methyl ester
- lipase
- reaction
- proline methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090001060 Lipase Proteins 0.000 title claims abstract description 51
- 102000004882 Lipase Human genes 0.000 title claims abstract description 48
- 239000004367 Lipase Substances 0.000 title claims abstract description 47
- 235000019421 lipase Nutrition 0.000 title claims abstract description 47
- WVDGSSCWFMSRHN-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl pyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CCCN1C(=O)OC(C)(C)C WVDGSSCWFMSRHN-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- WVDGSSCWFMSRHN-MRVPVSSYSA-N 1-o-tert-butyl 2-o-methyl (2r)-pyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@H]1CCCN1C(=O)OC(C)(C)C WVDGSSCWFMSRHN-MRVPVSSYSA-N 0.000 claims abstract description 28
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 4
- 230000004151 fermentation Effects 0.000 claims abstract description 4
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 239000012429 reaction media Substances 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 238000005406 washing Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000012074 organic phase Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- 239000011942 biocatalyst Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 14
- 229930182820 D-proline Natural products 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229960002429 proline Drugs 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 9
- 229930182821 L-proline Natural products 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000003301 hydrolyzing effect Effects 0.000 description 7
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 6
- 241000672609 Escherichia coli BL21 Species 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000373064 Ochrobactrum oryzae Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 4
- 108010048733 Lipozyme Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002210 biocatalytic effect Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- -1 cyclic amino acid Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 2
- 108010084311 Novozyme 435 Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000012069 chiral reagent Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- WVDGSSCWFMSRHN-QMMMGPOBSA-N 1-o-tert-butyl 2-o-methyl (2s)-pyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C WVDGSSCWFMSRHN-QMMMGPOBSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 1
- GFEDXKNBZMPEDM-KZVJFYERSA-N Ala-Met-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFEDXKNBZMPEDM-KZVJFYERSA-N 0.000 description 1
- FEGOCLZUJUFCHP-CIUDSAMLSA-N Ala-Pro-Gln Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FEGOCLZUJUFCHP-CIUDSAMLSA-N 0.000 description 1
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- JSHVMZANPXCDTL-GMOBBJLQSA-N Arg-Asp-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JSHVMZANPXCDTL-GMOBBJLQSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- NXDXECQFKHXHAM-HJGDQZAQSA-N Arg-Glu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NXDXECQFKHXHAM-HJGDQZAQSA-N 0.000 description 1
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 1
- NUCUBYIUPVYGPP-XIRDDKMYSA-N Asn-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O NUCUBYIUPVYGPP-XIRDDKMYSA-N 0.000 description 1
- FLJVGAFLZVBBNG-BPUTZDHNSA-N Asn-Trp-Arg Chemical compound N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O FLJVGAFLZVBBNG-BPUTZDHNSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- SARSTIZOZFBDOM-FXQIFTODSA-N Asp-Met-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SARSTIZOZFBDOM-FXQIFTODSA-N 0.000 description 1
- KESWRFKUZRUTAH-FXQIFTODSA-N Asp-Pro-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O KESWRFKUZRUTAH-FXQIFTODSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- WTMZXOPHTIVFCP-QEWYBTABSA-N Glu-Ile-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WTMZXOPHTIVFCP-QEWYBTABSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- GNPVTZJUUBPZKW-WDSKDSINSA-N Gly-Gln-Ser Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GNPVTZJUUBPZKW-WDSKDSINSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- HHSOPSCKAZKQHQ-PEXQALLHSA-N Gly-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN HHSOPSCKAZKQHQ-PEXQALLHSA-N 0.000 description 1
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- IIVZNQCUUMBBKF-GVXVVHGQSA-N His-Gln-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 IIVZNQCUUMBBKF-GVXVVHGQSA-N 0.000 description 1
- PYNUBZSXKQKAHL-UWVGGRQHSA-N His-Gly-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O PYNUBZSXKQKAHL-UWVGGRQHSA-N 0.000 description 1
- VBOFRJNDIOPNDO-YUMQZZPRSA-N His-Gly-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N VBOFRJNDIOPNDO-YUMQZZPRSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 1
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- ALEVUGKHINJNIF-QEJZJMRPSA-N Lys-Phe-Ala Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ALEVUGKHINJNIF-QEJZJMRPSA-N 0.000 description 1
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 1
- FBLBCGLSRXBANI-KKUMJFAQSA-N Met-Phe-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FBLBCGLSRXBANI-KKUMJFAQSA-N 0.000 description 1
- YLDSJJOGQNEQJK-AVGNSLFASA-N Met-Pro-Leu Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YLDSJJOGQNEQJK-AVGNSLFASA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- MGBRZXXGQBAULP-DRZSPHRISA-N Phe-Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MGBRZXXGQBAULP-DRZSPHRISA-N 0.000 description 1
- OVJMCXAPGFDGMG-HKUYNNGSSA-N Phe-Gly-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OVJMCXAPGFDGMG-HKUYNNGSSA-N 0.000 description 1
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- KPDRZQUWJKTMBP-DCAQKATOSA-N Pro-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 KPDRZQUWJKTMBP-DCAQKATOSA-N 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- XYAFCOJKICBRDU-JYJNAYRXSA-N Pro-Phe-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O XYAFCOJKICBRDU-JYJNAYRXSA-N 0.000 description 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- SOACHCFYJMCMHC-BWBBJGPYSA-N Ser-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O SOACHCFYJMCMHC-BWBBJGPYSA-N 0.000 description 1
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 1
- BEGDZYNDCNEGJZ-XVKPBYJWSA-N Val-Gly-Gln Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O BEGDZYNDCNEGJZ-XVKPBYJWSA-N 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明提供了一种脂肪酶在拆分BOC‑DL‑脯氨酸甲酯制备BOC‑D‑脯氨酸甲酯中的应用,所述脂肪酶的氨基酸序列如SEQ ID NO.1所示,其编码基因如SEQ ID NO.2所示。以重组脂肪酶工程菌发酵培养获得的湿菌体经冷冻干燥后得到的冻干菌体为催化剂,外消旋BOC‑DL‑脯氨酸甲酯为底物,以pH7.0磷酸缓冲溶液为反应介质,进行拆分制备BOC‑D‑脯氨酸甲酯,对映体过量值>99%,BOC‑D‑脯氨酸甲酯的收率达到96.0%。
Description
(一)技术领域
本发明属于生物酶催化领域,涉及一种脂肪酶立体选择性催化水解外消旋BOC-DL-脯氨酸甲酯合成单一构型的BOC-D-脯氨酸甲酯的应用。
(二)背景技术
脯氨酸(proline)学名为氢化吡咯甲酸,是一种重要的五元环状氨基酸。脯氨酸的存在形式有DL-脯氨酸、L-脯氨酸和D-脯氨酸,其中L-脯氨酸(L-Pro),是一种天然存在的人体非必需氨基酸。D-脯氨酸(D-Pro)作为一种重要的手性化合物,既可用于拆分剂和手性试剂,也可以用于合成某些手性药物的手性中间体,作为合成光学活性吡咯衍生物的原料,其在各种不对称合成反应中显示了优良的不对称源性能。常用于制备5-氨基-4-轻基己酸的二肽衍生物,该二肽衍生物是艾滋病毒蛋白酶抑制剂,用于研究人类免疫缺陷病毒感染的发病机理研究,并用于预防、治疗和检测艾滋病。D-Pro一般存在于亚麻种子和枇杷种子中,并且是以γ-L-谷氨酰-l-氨基-D-脯氨酸和反4-羧甲基化-D-脯氨酸的形式存在。目前,D-脯氨酸已在镇静药、金属蛋白酶抑制剂、抗艾滋病药、多巴类药物中有重要的应用。
L-Pro可以通过发酵方法制备或从蛋白质水解液分离得到,价格相对便宜。D-Pro很难从天然物质中得到,传统的工艺是以丁二醛为原料经四步反应合成出DL-Pro,再经拆分得到D-Pro,反应步骤长,总收率低,效益较差。1989年,Shiraiwal等曾报道以廉价的L-Pro为原料,在酸性介质中,在催化剂及手性试剂的存在下发生不对称转换,最终制得D-Pro,光学纯度为100%,转化率为85%。洪铺裕等曾用不对称转换法方法制备D-Pro。该法以来源广泛的L-Pro为起始原料,在丁醛的作用下先消旋化,然后与(2R,3R)-酒石酸成盐,再利用D-Pro的(2R,3R)-酒石酸盐在正丁酸中的溶解度远小于L-Pro的(2R,3R)-酒石酸盐的特性,使前者优先析出,同时又可进一步促进溶液中L-Pro的消旋化,最终使其几乎全部转化成D-Pro的(2R,3R)-酒石酸盐。最后经35%氨水游离,得到D-Pro,转化率达到88.3%。目前随着手性技术在化工、医药行业中的广泛应用,能够方便,经济地得到具有光学活性的手性中间体已经成为迫在眉睫的需求。化学不对称转换虽具有强大功能,然而,随着人们环保意识的日益提高,尤其是绿色化学的提出,经典的化学方法对环境的污染已经引起人们足够的重视。而环境友好的生物法越来越受到人们的推崇。生物转化法制备D-Pro可以解决现有方法易造成环境污染,产生大量无效甚至对环境有害的对映体问题,对于保护人类的自然环境和健康具有极为重要的意义。
(三)发明内容
本发明目的是为了解决现有方法的不足,通过筛选产脂肪酶微生物,提供一种廉价高效的立体选择性脂肪酶在生物法拆分BOC-DL-脯氨酸甲酯制备BOC-D-脯氨酸甲酯中的应用,该生物催化剂的立体选择性强。本发明利用新筛选的脂肪酶催化立体选择性水解反应拆分制备高光学纯度的BOC-D-脯氨酸甲酯,使用的生物催化剂易得且成本低,ee值和转化率高,路线短操作简便,开发成本低廉、适合产业化放大工艺路线,具有很大的社会意义和经济价值。
本发明采用的技术方案是:
本发明提供一种源自水稻苍白杆菌(Ochrobactrum oryzae)的脂肪酶在拆分BOC-DL-脯氨酸甲酯制备BOC-D-脯氨酸甲酯中的应用(如图2所示),所述脂肪酶氨基酸序列如SEQ ID NO.1所示,编码基因序列为SEQ ID NO.2所示。具体的应用方法为:以含脂肪酶编码基因的工程菌经发酵培养获得的湿菌体冷冻干燥后得到的脂肪酶粗酶粉为催化剂,以外消旋BOC-DL-脯氨酸甲酯为底物,以pH 7.0缓冲液为反应介质,在25-60℃、800rpm条件下进行拆分反应,反应完全后,将反应液分离纯化,获得BOC-D-脯氨酸甲酯。所述催化剂用量以缓冲液体积计为5g/L-60g/L(优选10g/L),所述底物体积用量以缓冲液体积计为1%-20%(V/V)(优选10%)。
进一步,优选反应时间为5-60min,更优选反应条件为50℃、800rpm反应35min。
进一步,所述缓冲液为pH 7.0,0.2mM的Na2HPO4/NaH2PO4缓冲溶液。
进一步,所述催化剂按如下方法制备:将含脂肪酶编码基因的工程菌(优选大肠杆菌BL21)接种在LB培养基中,37℃培养OD600至为0.4-0.6,加IPTG至终浓度0.02mM,28℃培养10-12h,菌液8000rpm,4℃离心10min,收集菌体,再用PBS缓冲液洗涤菌体2次,8000rpm,4℃离心10min,收集菌体,冻干(优选-80℃),得到脂肪酶粗酶粉;所述LB培养基组成:胰蛋白胨10g/L、酵母粉5g/L、NaCl 5g/L,溶剂为去离子水,pH值自然。
进一步,本发明所述反应液分离纯化的方法为:反应结束后,反应液先用4M HCl溶液调pH至2.0,然后用等体积乙酸乙酯萃取反应液,分液漏斗分离出有机相,再经纯水洗涤两次,饱和NaCl洗涤两次,干燥,旋蒸,得到最终产物BOC-D-脯氨酸甲酯。
本发明所述底物BOC-DL-脯氨酸甲酯按如下方法制备:取BOC-D-脯氨酸、BOC-L-脯氨酸和甲醇(分析纯,甲醇过量)放入250mL圆底烧瓶中,加入甲苯作为反应溶剂,再加入浓硫酸(质量浓度98%)作为催化剂,在磁力搅拌器上通过油浴80℃,600rpm条件下反应6-8h;反应结束后得到的反应液,先用饱和Na2CO3洗涤,除去其中的未反应酸,然后用等体积的乙酸乙酯进行萃取,分液漏斗分离有机相和水相,水相用乙酸乙酯萃取两次,合并有机相,再经纯水洗涤两次,饱和NaCl洗涤两次,降低酯在水中的溶解度,减少酯的损失,干燥旋蒸后,得到产物BOC-DL-脯氨酸甲酯;所述BOC-D-脯氨酸与BOC-L-脯氨酸质量比为1:1,所述甲醇体积用量以BOC-D-脯氨酸质量计为2mL/g;所述甲苯体积用量以BOC-D-脯氨酸质量计为10mL/g;所述浓硫酸体积用量以BOC-D-脯氨酸质量计为500μL/3g。
本发明脂肪酶氨基酸序列如SEQ ID NO.1所示:
MKLHQVETSHGRIAIRESTGEGMPLLMIHGNSSAGAIFAPQLEGEIGRNWRVIAPDLPGHGQSGDALDPDRSYSMEGYADAMTEVLTKLGISEAVVFGWSLGGHIGIEMISRFPGMRGLMITGTPPVAREEVGQGFKSGPDMALAGQEIFSTRDVESYARSTCGEPFEASLLDIVARTDGRARRIMFEKFAAGTGGNQRDIVAAATLPIAVVNGRDEPFVELDFVSKVRFGNLWEGRTHVIDGAGHAPFRETPAVFDAYLQRFIRDCAA。
由于氨基酸序列的特殊性,任何含有SEQ ID NO.1所示氨基酸序列的多肽的片段或其变体,如其保守性变体、生物活性片段或衍生物,只要该多肽的片段或多肽变体与前述氨基酸序列同源性在90%以上、且具有相同的酶活性,均属于本发明保护范围之列。具体的,所述改变可包括氨基酸序列中氨基酸的缺失、插入或替换;其中,对于变体的保守性改变,所替换的氨基酸具有与原氨基酸相似的结构或化学性质,如用亮氨酸替换异亮氨酸,变体也可具有非保守性改变,如用色氨酸替换甘氨酸。
本发明所述蛋白的片段、衍生物或类似物是指基本上保持本发明所述的蛋白酶相同的生物学功能或活性的蛋白,可以是下列情形:(I)一个或多个氨基酸残基被保守或非保守氨基酸残基(优选的是保守氨基酸残基)取代,并且取代的氨基酸可以是也可以不是由遗传密码子编码的;(Ⅱ)一个或多个氨基酸残基上的某个基团被其它基团取代;(Ⅲ)成熟蛋白与另一种化合物(比如延长蛋白半衰期的化合物,例如聚乙二醇)融合;(IV)附加的氨基酸序列融合进成熟的蛋白而形成的蛋白序列(如用来纯化此蛋白的序列或蛋白原序列)。
所述蛋白可以是重组蛋白、天然蛋白或合成蛋白,可以是纯天然纯化的产物,或是化学合成的产物,或使用重组技术从原核或真核宿主(例如:细菌、酵母、高等植物、昆虫和哺乳动物细胞)中产生。根据重组生产方案所用的宿主,本发明的蛋白可以是糖基化的。本发明的蛋白还可以包括或不包括起始的甲硫氨酸残基。
本发明还涉及所述脂肪酶的编码基因,具体的,所述大肠杆菌密码子优化后的编码基因核苷酸序列如SEQ ID NO.2所示:
ATGAAACTGCACCAGGTGGAAACCTCCCACGGCCGTATTGCCATTCGTGAAAGCACCGGTGAAGGTATGCCGCTGCTGATGATTCACGGTAACAGCAGCGCAGGTGCCATTTTTGCCCCGCAGCTGGAAGGTGAAATTGGACGTAATTGGCGTGTTATTGCACCTGATCTGCCGGGTCATGGTCAGTCAGGTGATGCCCTGGATCCGGATCGTAGCTATAGTATGGAAGGTTATGCAGATGCAATGACAGAAGTTCTGACCAAACTGGGCATTTCCGAAGCAGTTGTTTTTGGTTGGAGCCTGGGTGGTCATATTGGTATTGAAATGATTTCACGTTTCCCGGGTATGCGTGGTCTGATGATTACCGGTACCCCTCCGGTCGCACGTGAGGAAGTGGGTCAGGGTTTTAAAAGCGGTCCGGATATGGCACTGGCAGGCCAGGAGATTTTTTCTACCCGTGATGTTGAGAGCTATGCACGTAGCACATGTGGTGAACCGTTTGAAGCAAGCCTGCTGGATATTGTTGCACGTACAGATGGACGTGCACGTCGTATTATGTTTGAAAAATTTGCCGCAGGTACCGGAGGAAATCAGCGTGATATCGTTGCGGCAGCAACCCTGCCGATTGCAGTTGTGAACGGTCGTGATGAACCGTTTGTTGAACTGGATTTTGTTAGCAAAGTGCGTTTTGGTAATCTGTGGGAGGGTCGTACCCATGTTATTGATGGTGCAGGTCATGCACCGTTTCGTGAAACCCCGGCAGTTTTTGATGCCTATCTGCAGCGTTTTATTCGTGATTGTGCTGCC。
由于核苷酸序列的特殊性,任何SEQ ID NO.2所示多核苷酸的变体,只要其与该多核苷酸具有70%以上同源性、且具有相同的功能,均属于本发明保护范围之列。所述多核苷酸的变体是指一种具有一个或多个核苷酸改变的多核苷酸序列。此多核苷酸的变体可以是天然发生的等位变异体或非天然发生的变异体,包括取代变异体、缺失变异体和插入变异体。如本领域所知的,等位变异体是一个多核苷酸的替换形式,它可能是一个或多个核苷酸的取代、缺失或插入,但不会从实质上改变其编码的氨基酸的功能。
另外,可与SEQ ID NO:2所示多核苷酸序列杂交的多核苷酸(至少具有50%同源性,优选具有70%同源性),也在本发明保护范围之列,特别是在严格条件下可与本发明所述核苷酸序列杂交的多核苷酸。所述“严格条件”是指:(1)在较低离子强度和较高温度下的杂交和洗脱,如0.2SSC,0.1%SDS,60℃;或(2)杂交时加用变性剂,如50%(v/v)甲酰胺,0.1%小牛血清,0.1%Ficoll,42℃;或(3)仅在两条序列之间的同源性至少在95%以上,更好是97%以上时才发生杂交。并且,可杂交的多核苷酸编码的蛋白与SEQ ID NO:1所示的蛋白有相同的生物学功能和活性。
本发明还涉及含有所述编码基因的重组载体,以及利用所述重组载体转化得到的重组基因工程菌。
与现有技术相比,本发明的有益效果主要体现在:本发明提供了一种脂肪酶基因核苷酸序列;该脂肪酶基因可与表达载体连接构建得到含该基因的胞内表达重组质粒,再转化至大肠杆菌菌株中,获得重组大肠杆菌,再利用重组大肠杆菌或重组脂肪酶为生物催化剂催化拆分BOC-DL-脯氨酸甲酯,可以生成BOC-D-脯氨酸甲酯,对映体过量值>99%和转化率达到49.94%,BOC-D-脯氨酸甲酯的收率达到96.0%。本发明生物催化的手性合成反应具有条件温和、效率高,高度的化学选择性、区域选择性以及对映体选择性等优点,而且生物催化过程具有无毒、无污染和能耗低等特点,是一种环境友好的合成方法。
(四)附图说明
图1为有机合成BOC-DL-脯氨酸甲酯的反应示意图;
图2为脂肪酶对映选择性水解拆分BOC-DL-脯氨酸甲酯的反应示意图;
图3为BOC-DL-脯氨酸甲酯标样气相色谱图;
图4为BOC-D-脯氨酸甲酯标样气相色谱图;
图5为脂肪酶催化BOC-DL-脯氨酸甲酯水解反应35min的气相色谱图。
(五)具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此,本领域的普通技术人员根据这些实施方式所做出的方法上的变换均包含在本发明的保护范围内。
实施例1化学合成底物BOC-DL-脯氨酸甲酯
取3g BOC-D-脯氨酸、3g BOC-L-脯氨酸和6mL甲醇(分析纯,甲醇过量)放入250mL圆底烧瓶中,加入30mL甲苯作为反应溶剂,再加入500uL的浓硫酸(质量浓度98%)作为催化剂。在磁力搅拌器上通过油浴80℃,600rpm条件下反应6-8h。反应结束后得到的反应液,先用饱和Na2CO3洗涤,除去其中的未反应酸,然后用等体积的乙酸乙酯进行萃取,分液漏斗分离有机相和水相,水相用乙酸乙酯萃取两次,合并有机相,再经纯水洗涤两次,饱和NaCl洗涤两次,降低酯在水中的溶解度,减少酯的损失,干燥旋蒸后,得到产物BOC-DL-脯氨酸甲酯5g(如图1所示)。产物经过GC分析(如图3所示),没有其他杂质,纯度达到100%,质量收率96.0%。
实施例2酶催化拆分BOC-DL-脯氨酸甲酯的脂肪酶筛选
大肠杆菌BL21(F31)工程菌构建:根据源自水稻苍白杆菌(Ochrobactrum oryzae)的脂肪酶(基因库GenBank:PQA74230.1),通过杭州擎科生物技术有限公司人工合成SEQ IDNO.2所示核苷酸序列的基因,将该片段连接到pET28b载体上获得克隆载体pET28b-f31,并将其转化于大肠杆菌(Escherichia coli)BL21中,获得重组大肠杆菌,记为大肠杆菌BL21(F31)。对重组质粒测序,并利用软件对测序结果进行分析,该序列含有一个长为807bp的开放阅读框(SEQ ID NO.2),表明大肠杆菌重组脂肪酶工程菌构建成功。其他脂肪酶基因(如表1所示)重组工程菌,按上述方法及宿主细胞和质粒进行工程菌的构建,并进行发酵获得含脂肪酶的菌体。
大肠杆菌BL21(F31)培养条件:
LB培养基组成:胰蛋白胨10g/L、酵母粉5g/L、NaCl 5g/L,溶剂为水,pH自然。将大肠杆菌BL21(F31)菌种斜面接种在LB培养基中,37℃培养OD600至为0.5(约培养2h),加IPTG至终浓度0.02mM,28℃培养10-12h。将300mL菌液在8000rpm、4℃的条件下离心10min,收集菌体,再用PBS缓冲液洗涤菌体2次,8000rpm、10min离心收集菌体。将收集的菌体使用真空冷冻冻干机-80℃冻干,得到脂肪酶F31粗酶粉,放于4℃冰箱保存备用。
根据脂肪酶F31粗酶粉的制备方法,分别制备得到表1中各个脂肪酶。
称取表1中不同来源的具有水解活性的冻干的脂肪酶菌粉0.01g于2mL EP管中,加入1mL磷酸缓冲液(pH 7.0、0.2mM)作为反应溶剂,然后加入10uL底物BOC-DL-脯氨酸甲酯(实施例1制备),以不加菌体为空白对照,置于35℃,800rpm恒温混匀仪中反应60min。反应结束后,反应液经4M HCl酸化后用等体积的乙酸乙酯离心,使用气相色谱检测菌体的立体选择性及酶催化水解活性,结果如表1所示,筛选得到底物的对映体过量值>99%产脂肪酶微生物菌株,最终选择源自水稻苍白杆菌(Ochrobactrum oryzae,GenBank:PQA74230.1)的蛋白质序列(表1中F31),试验最终选择大肠杆菌BL21(F31)发酵的粗酶粉作为催化拆分反应的生物催化剂。通过大肠杆菌表达系统密码子优化后获得基因序列SEQ ID NO.2所示核苷酸序列,编码蛋白氨基酸序列为SEQ ID NO.1所示。
表1筛选具有水解活性的脂肪酶
具体气相分析条件:采用Agilent6890气相色谱仪,BGB-175手性毛细管色谱柱(30.0m×0.25mm×0.25um),FID检测器;检测条件为柱温从初始温度120℃(恒温保持4min)升温至170℃,升温速率2℃/min,进样温度250℃,检测器温度250℃,空气流量和氢气流量分别为300mL/min和30mL/min。载气为高纯N2,柱头压98.7Kpa;尾吹气流量25.0mL·min-1;分流比20:1,进样体积为1uL。如GC结果所示,BOC-D-脯氨酸甲酯和BOC-L-脯氨酸甲酯的保留时间分别为13.896min和14.092min(如图3所示),BOC-D-脯氨酸甲酯标样保留时间为13.895min(如图4所示),酶水解拆分反应后,获得BOC-D-脯氨酸甲酯的气相色谱图(如图5所示)。
实施例3反应温度对酶动力学水解拆分BOC-DL-脯氨酸甲酯的影响
在pH 7.0,0.2mM的Na2HPO4/NaH2PO4缓冲溶液1mL中,加入终浓度10g/L的实施例2方法制备的脂肪酶F31,10uL BOC-DL-脯氨酸甲酯,于恒温混匀仪不同温度(25-60℃),800rpm条件下反应60min,取反应液按实施例2方法检测BOC-D-脯氨酸甲酯的对映体过量值和转化率,结果见表2所示。
结果说明,在反应温度为50℃时,BOC-D-脯氨酸甲酯的对映体过量值最高,其ee值>99%。当反应温度高于50℃或者低于50℃时,催化转化率和对映体过量值都会下降,说明温度对脂肪酶F31的光学选择性具有很大的影响。
表2反应温度对反应的影响
实施例4反应时间对酶动力学水解拆分BOC-DL-脯氨酸甲酯的影响
在pH 7.0,0.2mM的Na2HPO4/NaH2PO4缓冲溶液1mL中,加入终浓度10g/L的实施例2方法制备的脂肪酶F31,10uL BOC-DL-脯氨酸甲酯,于恒温混匀仪50℃,800rpm条件下反应不同时间(5min-60min),取反应液按实施例2方法检测BOC-D-脯氨酸甲酯的对映体过量值和转化率,结果见表3所示。
结果表明,反应35min后,产物BOC-D-脯氨酸甲酯的对映体过量值已达到最高,对映体过量值>99%,转化率为49.94%,当反应时间大于35min,酶会催化BOC-D-脯氨酸甲酯,转化率增大,将导致BOC-D-脯氨酸甲酯的收率降低。
表3反应时间对酶催化反应反应的影响
实施例5不同脂肪酶催化BOC-DL-脯氨酸甲酯水解拆分的效果比较
在pH 7.0,0.2mM的Na2HPO4/NaH2PO4缓冲溶液1mL中,加入终浓度10g/L的不同脂肪酶(实施例3制备的脂肪酶F31粗酶粉、Novozym 435、Lipozyme TL IM、Lipozyme RM IM),1mL BOC-DL-脯氨酸甲酯,于恒温混匀仪50℃,800rpm条件下反应35min,取反应液按实施例2方法检测BOC-D-脯氨酸甲酯的对映体过量值和转化率,结果见表4所示。在50℃反应35min后,Novozym435对BOC-DL-脯氨酸甲酯的两种构型能进行一定程度水解,但对底物两种构型存在较低对映体选择性,而LipozymeTL IM、LipozymeRM IM对底物没有水解活性和对映体选择性。而当脂肪酶F31催化反应时,产物BOC-D-脯氨酸甲酯的ee值>99%,转化率为49.94%,说明脂肪酶粗酶粉F31具有良好的立体选择性。
表4不同脂肪酶催化BOC-DL-脯氨酸甲酯的拆分效果
实施例7 BOC-D-脯氨酸甲酯的分离提取
在50mL圆底烧瓶中加入10mL pH 7.0,0.2mM的Na2HPO4/NaH2PO4缓冲溶液,称取0.4g实施例3方法制备的脂肪酶F31,再加入终浓度10%(V/V)的BOC-DL-脯氨酸甲酯,用200mM NaOH水溶液进行流加滴定反应,控制反应pH维持在7.0,在磁力搅拌器50℃,200rpm条件下反应2h。反应结束后,反应液先用4M HCl水溶液调pH至2.0,反应液用等体积乙酸乙酯萃取,分液漏斗分离出有机相,再经纯水洗涤两次,饱和NaCl洗涤两次,干燥,旋蒸,得到最终产物,并称重为0.675g,产物BOC-D-脯氨酸甲酯ee值>99%,质量收率达到96.0%。
序列表
<110> 浙江工业大学
<120> 一种脂肪酶在拆分BOC-DL-脯氨酸甲酯中的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 269
<212> PRT
<213> 未知(Unknown)
<400> 1
Met Lys Leu His Gln Val Glu Thr Ser His Gly Arg Ile Ala Ile Arg
1 5 10 15
Glu Ser Thr Gly Glu Gly Met Pro Leu Leu Met Ile His Gly Asn Ser
20 25 30
Ser Ala Gly Ala Ile Phe Ala Pro Gln Leu Glu Gly Glu Ile Gly Arg
35 40 45
Asn Trp Arg Val Ile Ala Pro Asp Leu Pro Gly His Gly Gln Ser Gly
50 55 60
Asp Ala Leu Asp Pro Asp Arg Ser Tyr Ser Met Glu Gly Tyr Ala Asp
65 70 75 80
Ala Met Thr Glu Val Leu Thr Lys Leu Gly Ile Ser Glu Ala Val Val
85 90 95
Phe Gly Trp Ser Leu Gly Gly His Ile Gly Ile Glu Met Ile Ser Arg
100 105 110
Phe Pro Gly Met Arg Gly Leu Met Ile Thr Gly Thr Pro Pro Val Ala
115 120 125
Arg Glu Glu Val Gly Gln Gly Phe Lys Ser Gly Pro Asp Met Ala Leu
130 135 140
Ala Gly Gln Glu Ile Phe Ser Thr Arg Asp Val Glu Ser Tyr Ala Arg
145 150 155 160
Ser Thr Cys Gly Glu Pro Phe Glu Ala Ser Leu Leu Asp Ile Val Ala
165 170 175
Arg Thr Asp Gly Arg Ala Arg Arg Ile Met Phe Glu Lys Phe Ala Ala
180 185 190
Gly Thr Gly Gly Asn Gln Arg Asp Ile Val Ala Ala Ala Thr Leu Pro
195 200 205
Ile Ala Val Val Asn Gly Arg Asp Glu Pro Phe Val Glu Leu Asp Phe
210 215 220
Val Ser Lys Val Arg Phe Gly Asn Leu Trp Glu Gly Arg Thr His Val
225 230 235 240
Ile Asp Gly Ala Gly His Ala Pro Phe Arg Glu Thr Pro Ala Val Phe
245 250 255
Asp Ala Tyr Leu Gln Arg Phe Ile Arg Asp Cys Ala Ala
260 265
<210> 2
<211> 807
<212> DNA
<213> 未知(Unknown)
<400> 2
atgaaactgc accaggtgga aacctcccac ggccgtattg ccattcgtga aagcaccggt 60
gaaggtatgc cgctgctgat gattcacggt aacagcagcg caggtgccat ttttgccccg 120
cagctggaag gtgaaattgg acgtaattgg cgtgttattg cacctgatct gccgggtcat 180
ggtcagtcag gtgatgccct ggatccggat cgtagctata gtatggaagg ttatgcagat 240
gcaatgacag aagttctgac caaactgggc atttccgaag cagttgtttt tggttggagc 300
ctgggtggtc atattggtat tgaaatgatt tcacgtttcc cgggtatgcg tggtctgatg 360
attaccggta cccctccggt cgcacgtgag gaagtgggtc agggttttaa aagcggtccg 420
gatatggcac tggcaggcca ggagattttt tctacccgtg atgttgagag ctatgcacgt 480
agcacatgtg gtgaaccgtt tgaagcaagc ctgctggata ttgttgcacg tacagatgga 540
cgtgcacgtc gtattatgtt tgaaaaattt gccgcaggta ccggaggaaa tcagcgtgat 600
atcgttgcgg cagcaaccct gccgattgca gttgtgaacg gtcgtgatga accgtttgtt 660
gaactggatt ttgttagcaa agtgcgtttt ggtaatctgt gggagggtcg tacccatgtt 720
attgatggtg caggtcatgc accgtttcgt gaaaccccgg cagtttttga tgcctatctg 780
cagcgtttta ttcgtgattg tgctgcc 807
Claims (9)
1.一种脂肪酶在拆分BOC-DL-脯氨酸甲酯制备BOC-D-脯氨酸甲酯中的应用,其特征在于所述脂肪酶的氨基酸序列如SEQ ID NO.1所示。
2.如权利要求1所述的应用,其特征在于所述脂肪酶编码基因的核苷酸序列如SEQ IDNO.2所示。
3.如权利要求1所述的应用,其特征在于所述应用的方法为:以含脂肪酶编码基因的工程菌经发酵培养获得的湿菌体冻干后的脂肪酶粗酶粉为生物催化剂,以外消旋BOC-DL-脯氨酸甲酯为底物,以pH 7.0缓冲液为反应介质,在25-60℃、800rpm条件下进行拆分反应,反应完全后,将反应液分离纯化,获得BOC-D-脯氨酸甲酯。
4.如权利要求3所述的应用,其特征在于所述催化剂用量以缓冲液体积计为5g/L-60g/L,所述底物体积用量以缓冲液体积计为1%-20%。
5.如权利要求3所述的应用,其特征在于反应时间为5min-60min。
6.如权利要求3所述的应用,其特征在于所述反应条件为50℃、800rpm反应35min。
7.如权利要求3所述的应用,其特征在于所述缓冲液为pH 7.0、0.2mM的Na2HPO4/NaH2PO4缓冲溶液。
8.如权利要求3所述的应用,其特征在于所述催化剂按如下方法制备:将含脂肪酶编码基因的工程菌接种在LB培养基中,37℃培养OD600至为0.4-0.6,加IPTG至终浓度0.02mM,28℃培养10-12h,发酵液8000rpm,4℃离心10min,收集菌体,再用磷酸缓冲液洗涤菌体2次,8000rpm,4℃离心10min,收集湿菌体,冻干后得到脂肪酶粗酶粉。
9.如权利要求3所述的应用,其特征在于所述反应液分离纯化的方法为:反应结束后,反应液先用4M HCl水溶液调pH至2.0,反应液用等体积乙酸乙酯萃取,分液漏斗分离出有机相,再经纯水洗涤两次,饱和NaCl洗涤两次,干燥,旋蒸,得到最终产物BOC-D-脯氨酸甲酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010008836.1A CN111057736B (zh) | 2020-01-06 | 2020-01-06 | 一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010008836.1A CN111057736B (zh) | 2020-01-06 | 2020-01-06 | 一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111057736A CN111057736A (zh) | 2020-04-24 |
CN111057736B true CN111057736B (zh) | 2022-03-18 |
Family
ID=70306403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010008836.1A Active CN111057736B (zh) | 2020-01-06 | 2020-01-06 | 一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111057736B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628544A (zh) * | 2019-01-22 | 2019-04-16 | 浙江工业大学 | 一种脂肪酶在拆分n-乙酰-dl-甲硫氨酸甲酯中的应用 |
CN109652470A (zh) * | 2018-12-29 | 2019-04-19 | 浙江工业大学 | 一种脂肪酶在拆分(r,s)-扁桃酸甲酯中的应用 |
CN110438194A (zh) * | 2019-07-29 | 2019-11-12 | 浙江工业大学 | 一种脂肪酶在制备d-托品酸甲酯中的应用 |
-
2020
- 2020-01-06 CN CN202010008836.1A patent/CN111057736B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652470A (zh) * | 2018-12-29 | 2019-04-19 | 浙江工业大学 | 一种脂肪酶在拆分(r,s)-扁桃酸甲酯中的应用 |
CN109628544A (zh) * | 2019-01-22 | 2019-04-16 | 浙江工业大学 | 一种脂肪酶在拆分n-乙酰-dl-甲硫氨酸甲酯中的应用 |
CN110438194A (zh) * | 2019-07-29 | 2019-11-12 | 浙江工业大学 | 一种脂肪酶在制备d-托品酸甲酯中的应用 |
Non-Patent Citations (3)
Title |
---|
An efficient lipase-catalyzed enantioselective hydrolysis of (R,S)-azolides derived from N-protected proline, pipecolic acid, and nipecotic acid;Chia-Hui Wu等;《Applied microbiology and biotechnology》;20120330;第97卷;第1582页Scheme 1,第1583页左栏最后一段,第1584页结果部分第1段 * |
Kinetic resolution of N‐acetyl‐DL‐alanine methyl ester using immobilized Escherichia coli cells bearing recombinant esterase from Bacillus cereus;Jianyong Zheng等;《Chirality》;20180420;第30卷(第7期);第907-912页 * |
NCBI Reference Sequence: WP_104755137.1;GenBank DataBase;《National Center for Biotechnology Information》;20180301;第1-2页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111057736A (zh) | 2020-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109628544B (zh) | 一种脂肪酶在拆分n-乙酰-dl-甲硫氨酸甲酯中的应用 | |
CN110358752B (zh) | 一种米曲霉脂肪酶及在制备布瓦西坦手性中间体中的应用 | |
CN109609475A (zh) | 草铵膦脱氢酶突变体及其合成l-草铵膦的应用 | |
CN110055297B (zh) | 一种酯酶在拆分(r,s)-5-己内酯中的应用 | |
CN112359036B (zh) | 一种催化活力和反应专一性提高的腈水解酶突变体及应用 | |
CN101921742A (zh) | 一种具有拆分消旋体γ-内酰胺活性的(+)γ-内酰胺酶及其编码基因与应用 | |
CN104962540A (zh) | 一种腈水解酶、编码基因、载体及应用 | |
CN109652470B (zh) | 一种脂肪酶在拆分(r,s)-扁桃酸甲酯中的应用 | |
CN110592045B (zh) | 一种重组酯酶、基因、工程菌及拆分(r,s)-吲哚啉-2-甲酸乙酯的应用 | |
CN110438194B (zh) | 一种脂肪酶在制备d-托品酸甲酯中的应用 | |
CN111057736B (zh) | 一种脂肪酶在拆分boc-dl-脯氨酸甲酯中的应用 | |
CN107201349A (zh) | 一种表达菜豆环氧化物水解酶的工程菌及应用 | |
CN109943618B (zh) | 一种重组脂肪酶在拆分(R,S)-α-乙基-2-氧-1-吡咯烷乙酸甲酯中的应用 | |
CN110423740A (zh) | 一种提高对映选择性的卤醇脱卤酶突变体及其应用 | |
CN112143725B (zh) | 一种重组酯酶、编码基因、工程菌及在拆分甲霜灵中的应用 | |
CN105950595B (zh) | (-)-γ-内酰胺酶、基因、突变体、载体及其制备与应用 | |
CN111057735B (zh) | 一种解淀粉芽孢杆菌酯酶在拆分N-BOC-DL-α-氨基丁酸甲酯中的应用 | |
CN114934061A (zh) | 工程菌及其在全细胞催化酮基泛解酸内酯生产d-泛解酸内酯中的应用 | |
CN114134132A (zh) | 比活提高的酰胺酶变体及其应用 | |
CN109762801B (zh) | 卤醇脱卤酶突变体及其在合成手性药物中间体中的应用 | |
CN110358804B (zh) | R-3-氨基正丁醇的酶法生产工艺 | |
CN110066835B (zh) | 一种脂肪酶在拆分外消旋2-溴代异戊酸乙酯中的应用 | |
CN110628743A (zh) | 一种立体选择性酯酶、编码基因、载体、工程菌与应用 | |
CN111378637A (zh) | 制备右旋酮洛芬的方法 | |
CN113755539B (zh) | 一种二氢嘧啶氨基水解酶及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |